CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus

EarningsIvonescimabNegative
AI Analysis

Summary

Sumitomo Pharma reported Q2 losses that exceeded expectations, with ivonescimab development continuing as a focus area.

Outcome Details

Q2 loss wider than expected

Importance:4/10
Sentiment:
-0.50
earningsquarterly_resultsivonescimabdrug_development
Related Companies

Read the original article

Published by yahoo_finance on July 24, 2026 1:10 PM

Read Original